Compare SFHG & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFHG | ADVB |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 9.7M |
| IPO Year | 2024 | 2025 |
| Metric | SFHG | ADVB |
|---|---|---|
| Price | $0.69 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 631.5K | ★ 1.3M |
| Earning Date | 10-30-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,577,200.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.56 | N/A |
| 52 Week Low | $0.32 | $0.32 |
| 52 Week High | $2.32 | $4.10 |
| Indicator | SFHG | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 73.77 | 48.09 |
| Support Level | $0.55 | $0.34 |
| Resistance Level | $0.59 | $0.40 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 92.70 | 54.43 |
Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as (i) book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and (ii) novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.